You have to remember MM has always been tricky hence why so much work has been done in exploring combination therapies, many drugs really need the other to act as their trigger. Yes FOCUS results where unfavourable but Onyx have so many shots on goal to determine the right combinations for the best response and outcome - 4 x Phase III trials ---- FOCUS / ASPIRE / ENDEAVOUR / CLARION & that's not even taking into account PAB's phase I/IIa combination trial.
AMGEN haven't paid $10B for Onyx with value largely attributed to Kyprolis for it to then get thrown out.
ONXY trial, page-34
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 3776088 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2310786 | 5 |
View Market Depth
| Last trade - 14.20pm 18/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable